Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab beta plus chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma (phase II)
ChiCTR2500109878Phase 2Not yet recruiting
- Sponsor
- Affiliated Hospital of Southwest Medical University
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in head and neck squamous cell carcinoma (HNSCC), sponsored by Affiliated Hospital of Southwest Medical University. Primary endpoint: Objective response rate. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
cetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2500109878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109878.